Larimar Phase 2 trial shows frataxin increases in skin and buccal cells; Q1 net loss $6.5M

Larimar Therapeutics, Inc.

Median placebo-adjusted frataxin increase from baseline: 3.5 pg/µg in skin, 0.9 pg/µg in buccal cells at day 14.
CTI-1601 generally well tolerated; one severe allergic reaction led to withdrawal; 8 of 9 completed the cohort.
Data submitted to FDA; meeting scheduled Q2 2023; program update expected Q3 2023.
Q1 2023 net loss $6.5M ($0.15/diluted share) vs $8.9M ($0.49) in Q1 2022; cash $111.5M as of March 31, 2023.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Larimar Therapeutics, Inc. reported financial results for first quarter ended March 31, 2023.

Period: first quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 15, 2023, Larimar Therapeutics, Inc. (the “ Company ”) announced its financial results and operational highlights for the first quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

Larimar Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-021953

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.